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Summary  The  rising  threat  of  antibiotic  resistance  is  linked  to  patterns  of  antibi-
otic  use  in  hospital  settings  where  global  efforts  are  undertaken  to  encourage
reporting  and  benchmarking  antibiotic  consumption  in  an  attempt  to  improve  pre-
scription  regimens.  In  Lebanon,  where  data  concerning  the  level  of  antibiotic
consumption  in  hospitals  is  scarce,  the  aim  of  our  paper  is  to  track  the  inten-
sity  of  antibiotic  consumption  in  order  to  identify  potential  evidence  of  antibiotic
misuse  or  abuse.  The  study  is  conducted  in  2012  for  a  period  of  12-month  using
data  from  pharmacy  records  in  27  non-teaching  Lebanese  hospitals  according  to
the  Anatomical,  Therapeutic  and  chemical  classiﬁcation  system  and  Deﬁned  Daily
Dose  (ATC/DDD)  recommended  by  the  World  Health  Organization  and  compiling  data
on  ABC  Calc  software  version  3.1.  Results  show  that  the  average  antibiotic  con-
sumption  excluding  pediatric  cases  is  72.56  Deﬁned  Daily  Dose  per  100  Bed-Days
(DDD/100BD).  Total  broad  spectrum  antibiotic  consumption  is  12.14  DDD/100BD  with
no  signiﬁcant  difference  found  between  public  and  private  hospitals  (p  >  0.05  for
all).  The  most  commonly  used  antibiotics  were  Amoxycillin/Clavulanic  acid,  Ceftria-
xone,  Amoxycillin  and  Cefuroxime  for  parenteral  use.  Consumption  of  beta-lactams,
Cephalosporins,  Carbapenems,  Monobactams  and  quinolones  did  not  vary  signiﬁ-
cantly  by  region,  occupancy  rate,  number  of  beds  including  the  number  of  intensive
Abbreviations: ATC/DDD, Anatomical, Therapeutic and chemical classiﬁcation system/Deﬁned Daily Dose; DDD/100BD, Deﬁned
Daily Dose per 100 Bed-Days; WHO, World Health Organization.
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care  unit  beds.  Our  data  ﬁndings  provides  baseline  information  on  patterns  of  antibi-
otic  consumption  in  Lebanon  and  the  issue  calls  for  concerted  efforts  to  encourage
data  reporting  on  national  basis  and  to  correlate  future  ﬁndings  with  results  of  antibi-
otic  susceptibility  testing  which  can  provide  insights  and  tools  needed  to  assess  the
public  health  consequences  of  antimicrobial  misuse  and  to  evaluate  the  impact  of
antibiotic  resistance  containment  interventions.
©  2016  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
ed.
I
A
t
c
a
f
e
m
r
a
p
a
t
s
a
O
i
p
c
c
s
[
w
a
t
t
t
m
n
o
b
p
i
g
t
i
d
c
l
a
t
i
s
s
i
a
d
n
a
g
p
c
t
h
M
S
T
d
d
l
D
F
B
a
c
o
y
of Bed-days,  a standardized  ﬁgure  that  provides  a
degree of  comparison  among  different  institutions.
Other requested  data  included,  the  hospital  sta-Limited.  All  rights  reserv
ntroduction
ntibiotic  resistance  is  a  growing  global  health
hreat of  broad  concern  where  increased  antibiotic
onsumption is  driving  resistance  [1].  Consequently,
ntibiotics are  becoming  less  effective  or  even  inef-
ective,  resulting  in  an  accelerating  health  security
mergency  that  is  rapidly  outpacing  available  treat-
ent options  [2]. Surveillance  of  antimicrobial
esistance  tracks  changes  in  microorganisms  and
llows the  early  detection  of  resistant  strains  of
ublic health  importance,  while  surveillance  of
ntibiotic  consumption  allows  the  quantiﬁcation  of
he selection  pressure  on  microbial  populations  and
erves as  an  outcome  measure  of  antibiotic  stew-
rdship  programs.  According  to  the  World  Health
rganization  (WHO),  linking  the  surveillance  ﬁnd-
ngs to  patterns  of  antibiotic  consumption  has
roven to  be  a  crucial  factor  driving  political
ommitment  to  successful  resistance  containment
ampaigns. In  this  context,  hospitals  represent  ‘hot
pots’ for  selective  pressure  on  micro-organisms
3]  where  the  lack  of  control  of  antimicrobial  use
ill inevitably  lead  to  overuse,  poor  outcomes
nd higher  healthcare  costs  [4]. Numerous  initia-
ives in  recent  years  have  encouraged  hospitals
o conduct  surveillance  of  antimicrobial  consump-
ion in  order  to  identify  possible  overuse  and
isuse [5].  In  fact,  in  high  income  countries,
etworks such  as  European  Surveillance  on  Antibi-
tics Consumption  Network  database  (maintained
y European  Centre  for  Disease  Control  for  Euro-
ean Union  (EU)  countries)  [6]  and  resistance  map
n the  United  States  of  America  have  enabled
reater understanding  of  antibiotic  use;  however,
here are  still  gaps  in  data  worldwide,  especially
n resource  limited  settings  [7]  Few  published
escriptions  [5,8]  or  comparisons  of  antibiotic
onsumption are  available  [9,10,34,35]  particu-
arly in  the  Mediterranean  region,  identiﬁed  as  an
t
t
orea  of  hyper-endemicity  for  multiresistant  hospi-
al pathogens  [11]. In  Lebanon,  there  is  a lack  of
nformation  concerning  the  level  of  antibiotic  con-
umption  in  the  hospitals.  The  objective  of  the
tudy is  to  address  this  issue  and  focus  on  the
ntensity of  antibiotic  use  in  participating  hospitals
nd benchmark  with  published  data  expressed  in
aily divided  dose  per  100-bed-days  (DDD/100BD)  in
eighboring Mediterranean  in  particular  and  other
vailable  data  worldwide  in  general.  Our  aim  is  to
ive an  insight  of  antibiotic  prescribing  patterns  and
rovide a baseline  data  for  future  benchmark  and
orrelation  with  changes  in  antibiotic  susceptibility
esting and  trends  of  antimicrobial  resistance  in  the
ospital settings.
aterial and methods
tudy design
his  is  an  observational  cross-sectional  study  con-
ucted for  a period  of  12-month  in 2012  using
ata from  pharmacy  records  aggregated  at  hospital
evel.
ata collection
ollowing  the  approval  of the  Institutional  Review
oard, ﬁfty  two  hospitals  were  asked  to  ﬁll  out
n anonymous  questionnaire.  Administrative  data
onsisted of the  hospital  number  of  beds  and  the
ccupancy  rate  for  a  period  of  12  month  during  the
ear 2012  allowing  the  determination  of  the  numberus, number  of  intensive  care  unit  (ICU)  beds  and
he availability  of  a transplantation  and/or  oncol-
gy unit,  considered  primary  areas  of  focus  due  to
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high  rates  of  antibiotic  usage  [12—16].  Data  con-
cerning the  consumption  of  antibiotics  for  systemic
use  were  collected  from  the  hospital  pharmacy
computer records  representing  the  total  number
of antibiotics  per  unit  dose  per  category,  actually
prescribed and  consumed  during  the  study  period
[31].  The  validity  of  the  data  was  not  tested  since
all collected  data  were  retrieved  from  computer-
ized reports  however  we  highlight  the  presence  of
bias due  to  peculiarities  of  prescribing  systems  and
the possibility  of  including  an  element  of  ambula-
tory care  mix  in  the  consumption  record.  Using  ABC
Calc. software  version  3.1,  antibiotic  consumption
data were  aggregated  at  the  ﬁfth  level  of  the  ATC
classiﬁcation and  expressed  in  Deﬁned  Daily  Doses
(DDD).
Hospital demographic data
Twenty  seven  general  private  and  public  hospitals
participated in  the  survey  from  different  regions  in
Lebanon. Patient’s  age  ranged  from  18  to  85  years
old. All  participating  hospitals  have  both  medical
and  surgical  units,  but  the  number  of  beds  including
ICU beds,  the  occupancy  rate  as  well  as  the  avail-
ability of  an  oncology  and/or  a  transplantation  unit
varied.
Antibiotic consumption
Antibiotic  consumption  data  retrieved  from  phar-
macy records,  were  collated  on  a  standardized  ﬁle
derived from  the  ABC  Calc  software  version  3.1
[developed by  the  Danish  Statens  Serum  Institute
(http://www.escmid.org/)]  on  a  Microsoft  Excel
application  (Microsoft  Corporation,  Redmond,  WA,
USA) together  with  administrative  data.  The  Excel
application  included  all  antibacterial  drugs  mar-
keted in  Lebanon  for  systemic  use  J01  ATC  group
[17,18].  As  recommended  by  the  WHO,  ABC  Calc
reports  hospital  antibiotic  consumption  as  a  number
of DDD/100BD.
For  a  speciﬁc  drug,  the  DDD  corresponds  to  the
assumed  average  daily  dose  for  its  main  indica-
tion in  adults.  ABC  Calc  uses  the  2006  version  of
the ‘‘ATC  (Anatomical  Therapeutic  Chemical)  Index
with DDDs’’.  Antibiotics  were  recorded  by  their
non-proprietary names.  Each  drug  was  then  given
its chemical  name  and  a  code  according  to  the  ATC
classiﬁcation  that  comprises  5  levels.  The  ﬁrst  level
is the  anatomical  group  (e.g.  anti-infective  for  sys-
temic use),  the  second  is  the  therapeutic  group
(antibiotics  for  systemic  use),  the  third  is  a ther-
apeutic  subgroup,  the  fourth  gives  the  chemical
form and  the  ﬁfth  is a  chemical  subgroup.  For  the
purpose of  our  study,  all  ﬁve  levels  were  used  [19].
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Hospital  antibiotic  consumption  was  divided
nto eight  main  antibiotic  groups:  penicillins
J01C); cephalosporins,  carbapenems  and
onobactams (J01D);  tetracyclines  (J01A);
acrolides +  lincosamides  + streptogramins  (J01F);
uinolones  (J01M);  sulphonamides  (J01E);  amino-
lycosides  (J01G);  and  ‘others’  [20], including
J01XA) glycopeptides,  (J01XD)  imidazoles,  (J01XX)
inezolid and  (J01XB)  polymyxin.  Broad  spectrum
ntibiotics  included  antipseudomonal  penicillins
J01CA) fourth  generation  cephalosporins  (J01DE),
arbapenems  (J01DH),  glycopeptides  (J01XD)  and
uinolones  (J01M).
tatistical analysis
ata  was  entered  and  analyzed  using  SPSS  version
7.0.  In  the  descriptive  analysis,  frequency  and
ercentages  were  presented  for  nominal  variables,
hile  means  and  standard  deviations  were  used  for
ontinuous  variables.  For  bivariate  analysis,  ANOVA
as used  to  compare  means  between  three  groups
r more,  while  Student  test  was  used  to  com-
are between  two  groups,  provided  distribution  was
ormal and  variances  were  homogeneous;  if  not,
on-parametric  tests  were  used:  Kruskall—Wallis
nd Mann—Whitney  tests,  respectively.  In  all  cases,
 p-value  <0.050  was  considered  statistically  signif-
cant.
esults
ospital characteristics
ccording  to  the  order  of  Hospitals,  there  are
ne hundred  thirty  eight  hospitals  in  Lebanon
here nine  are  classiﬁed  as  teaching  hospitals.
mong one  hundred  nineteen  non-teaching  hos-
itals, nineteen  are  considered  long-term  care
ettings  and  the  remaining  one  hundred  ten  are
hort — stay  acute  care  hospitals.  Two  types  of
ospitals were  excluded  from  the  study:  teaching
ospitals because  of  extensively  long  and  compli-
ated Institutional  Board  Review  procedures  and
ong-term  stay  hospitals.  Among  52  randomly  con-
acted hospitals  from  different  regions  in  Lebanon
ncluding  Beirut,  Mount  Lebanon,  Bekaa,  North  and
outh Lebanon,  only  27  general  hospitals  partici-
ated in  the  survey  among  which  89%  were  private
nd 11%  public  hospitals.  All  hospitals  required  to
emain anonymous  and  refused  to  give  any  data
oncerning  their  annual  report  of  susceptibility  pro-
les of  bacterial  strains.  Hospitals  participating  in
he survey  were  from  different  urban  regions  in
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Table  1  Hospitals  description  and  characteristics.
Characteristic  Frequency  (%)
Region  N  =  27
Beirut  4  (14.8%)
Bekaa  5  (18.5%)
Mount  Lebanon  13  (48.1%)
North  Lebanon 2  (7.4%)
South  Lebanon 3  (11.1%)
Oncology  unit
Absent  8(29.6%)
Present  19(70.4%)
Transplantation  unit
Absent  26(96.3%)
Present  1(3.7%)
Number  of  beds
80  beds  or  less 10(37.0%)
81  to  120  beds 9(33.3%)
More  than  120  beds 8(29.6%)
Occupancy  rate
53%  or  less  9(33.3%)
54  to  70%  10(37.0%)
More  than  70%  8(29.6%)
ICU  beds
6 ICU  beds  or  less  10(37.0%)
7  to  8  ICU  beds  9(33.3%)
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Table  2  Antibiotic  utilization.a
M  (SD)
Antibiotic  use
DDD/100  bed-days  72.56  (18.08)
Beta  lactam  19.04  (6.75)
Cephalosporins,  monobactam  &
carbapenems
27.41  (8.55)
Aminoglycosides  3.31  (1.89)
Carbapenems  5.12  (2.52)
Penicillins  with  antipseudomonal
activity/BLinh
2.15  (1.27)
Fourth  generation  cephalosporins  2.27  (1.64)
Glycopeptides  2.61  (1.56)
Total  Broad  spectrum  12.14  (5.25)
Most  commonly  used  drug
Amoxicillin/clavulanate  IV  16  (59.3%)
Ceftriaxone  IV  9  (33.3%)
Amoxicillin  IV  1  (3.7%)
Cefuroxime  IV  1  (3.7%)
a Statistical analysis: descriptive analysis, frequency and
percentages are presented for nominal variables and means
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pared to  the  ﬁndings  of  the  ARMed  project  [21]9  beds  or  more  8(29.6%)
ebanon,  48%  from  Mount  Lebanon,  19%  from  the
ekaa region,  15%  from  Beirut,  11%  from  the  South
nd 7%  from  the  North.  Among  them,  37%  of  hospi-
als have  less  than  80  beds  and  63%  have  more  than
 ICU  beds  while  70%  have  an  oncology  unit  and
6% do  not  have  a  transplantation  unit.  The  occu-
ancy  rate  was  less  than  53%  in  33%  of  the  hospitals
nd ranged  between  54%  and  70%  in  37%  of  hospi-
als while  it  was  70%  in  more  than  30%  of  hospitals
Table  1).
ospital characteristics associated with
ntibiotic consumption
he  average  antibiotic  consumption  in  the  hos-
itals  is  72.56  DDD/100  BD  with  a  total  broad
pectrum antibiotic  consumption  of  12.14  DDD/100
D. The  most  commonly  used  antibiotics  were
moxycillin/Clavulanic  acid,  Ceftriaxone,  Amoxy-
illin and  Cefuroxime  for  parenteral  use  with
moxycillin/Clavulanic  acid  consisting  of  59%  of
otal use  (Table  2).
The  average  antibiotic  consumption  in  public
ospitals is  66  DDD/100  BD  whereas  it  is  73  DDD/100
D in  private  hospitals  with  a  p  value  of  0.51.  No
igniﬁcant  difference  was  found  for  any  antibiotic
t
i
rand standard deviations are used for continuous variables;
p-value <0.05 is considered statistically signiﬁcant.
onsumption  between  public  and  private  hospitals
p >  0.05  for  all).
The  consumption  of  beta-lactams,
ephalosporins,  carbapenems,monobactams
nd quinolones  did  not  vary  signiﬁcantly  by  region,
ccupancy  rate,  number  of  beds  including  the  num-
er of  ICU  bed  or  the  availability  of  an  oncology  or
 transplantation  unit.
The  consumption  of  antipseudomonalpeni-
illinsvaried by  region  with  the  highest  value  noted
n Beirut  (p =  0.044).  In  addition,  the  use  of  amino-
lycosides  (p  =  0.034),  carbapenems  (p  =  0.042)
nd glycopeptides  (p  = 0.019)increased  signiﬁcantly
hen the  occupancy  rate  decreased  in  the  hospitals
Table  3).
iscussion
n  Lebanese  non-teaching  hospitals,  our  data
howed that  antibiotic  consumption  did  not  vary
igniﬁcantly  by  region,  occupancy  rate,  and  num-
er of  beds  including  number  of  ICU  bed  or  the
vailability of  an  oncology  or  a  transplantation  unit.
Results from  our  survey  demonstrated  that
verage antibiotic  consumption  in  Lebanese  non-
eaching hospitals  excluding  pediatric  cases  was
2.55 DDD/100  BD.  This  value  was  lower  com-hat  benchmarked  antibiotic  use  prospectively
n hospitals  from  southern  and  eastern  Mediter-
anean countries  and  showed  that  the  median  total
622
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Table  3  Antibiotics  use  and  hospital  characteristics.a
Characteristic  DDD/100  BD  Total  broad
spectrum
J01C  J01D  J01G  J01M  J01DH  J01CA  J01DE  J01XA
Region p =  0.044
Beirut  83.33  (28.72) 15.68  (7.15) 14.45  (2.81) 23.35  (12.92) 4.28  (2.47) 8.70  (4.72) 5.73  (2.56) 3.50  (1.28) 3.13  (1.73) 3.33  (2.73)
Bekaa  73.48  (16.62) 13.12  (4.49) 20.73  (8.17) 29.03  (5.88) 3.66  (2.06) 13.31  (5.21) 5.49  (2.14) 2.35  (1.20)  2.35  (1.71)  2.92  (1.46)
Mount  Lebanon 69.45  (8.84) 10.75  (0.21) 17.10  (3.96) 35.50  (7.78) 3.10  (1.56)  7.35  (0.35)  6.35  (2.33)  1.20  (1.70)  0.90  (1.27)  2.30  (0.85)
North  Lebanon 55.10  (9.49) 7.57  (4.22)  16.83  (1.19)  26.03  (11.59)  2.00  (1.25)  6.40  (0.96)  2.90  (1.74)  1.57  (0.40)  1.07  (1.10)  2.03  (1.63)
South  Lebanon 73.26  (16.11)  10.06  (5.78)  20.40  (6.90)  24.02  (9.68)  2.48  (0.94)  12.70  (5.93)  4.48  (3.73)  1.26  (0.69)  2.64  (1.62)  1.68  (0.41)
Oncology  unit p =  0.050
Present 71.07  (14.36) 12.90  (4.90) 17.93  (5.27) 27.46  (7.31) 3.09  (1.77) 11.58  (4.97) 5.26  (2.00) 2.33  (1.38) 2.41  (1.59) 2.90  (1.74)
Absent  76.08  (25.77) 10.34  (5.93) 21.66  (9.31) 27.28  (11.58) 3.83  (2.18) 10.64  (6.30) 4.76  (3.62) 1.71  (0.90) 1.94  (1.83)  1.93  (1.83)
Transplantation
unit
p  =  0.024  p  =  0.041  p  =  0.050
Present  77.40  23.50  21.00  25.80  2.10  16.10  10.10  3.50  5.40  4.50
Absent  72.37  (18.41)  11.70  (4.82)  19.96  (6.88)  27.47  (8.71)  3.35  (1.91)  11.12  (5.31)  4.92  (2.36)  2.10  (1.27)  2.15  (1.55)  2.54  (1.55)
Number  of  beds
80 beds  or  less 79.38  (19.11) 12.22  (5.33) 16.44  (5.20) 26.05  (11.10) 3.98  (2.03) 10.43  (5.59) 5.03  (2.38)  1.91  (1.55)  2.55  (1.92)  2.73  (1.79)
81  to  120  beds 65.61  (16.02) 11.63  (4.87) 18.64  (4.12) 27.62  (6.62)  2.94  (1.84)  10.36  (5.35)  4.91  (2.93)  2.30  (0.91)  2.03  (1.41)  2.39  (1.34)
More  than  120
beds
71.84 (17.95) 12.6  (6.17) 22.73  (9.48)  28.86  (7.60)  2.88  (1.74)  13.46  (4.85)  5.45  (2.50)  2.28  (1.35)  2.18  (1.67)  2.70  (1.67)
Occupancy  rate p  =  0.057 p =  0.092 p =  0.034 p =  0.042 p =  0.019
53%  or  less 83.20  (16.52) 14.42  (5.41) 22.52  (8.62) 30.72  (10.80) 4.28  (1.76) 13.80  (5.93)  6.23  (2.36)  2.40  (1.68)  2.08  (1.65)  3.71  (1.82)
54  to  70% 70.74  (21.20) 12.52  (5.12) 17.50  (5.14) 28.69  (5.36)  3.49  (2.17)  9.5  (4.59)  5.53  (2.44)  2.24  (1.08)  2.45  (1.65)  2.30  (1.32)
More  than  70% 62.85  (8.15) 9.09  (4.17) 17.04  (5.19)  22.08  (7.23)  1.99  (0.61)  10.75  (4.87)  3.34  (2.03)  1.75  (1.00)  2.25  (1.82)  1.75  (0.72)
ICU  beds p =  0.073
6  ICU  beds  or  less 72.78  (15.36) 12.31  (5.34) 16.91  (5.18) 26.11  (10.81) 3.36  (2.00)  8.76  (4.22)  4.79  (2.18)  2.06  (1.53)  2.66  (1.90)  2.80  (1.92)
7—8  ICU  beds 66.57  (16.50) 9.56  (3.32) 20.38  (9.82) 27.47  (6.81)  4.19  (2.05)  13.19  (5.55)  4.54  (1.78)  1.81  (1.15)  1.27  (0.58)  1.93  (1.00)
9  Beds  or  more 79.01  (22.49)  14.83  (6.01)  20.19  (3.79)  28.96  (7.94)  2.25  (1.00)  12.36  (5.54)  6.16  (3.47)  2.64  (1.02)  2.90  (1.74)  3.13  (1.49)
a Statistical analysis: Descriptive analysis, frequency and percentages are presented for nominal variables and means and standard deviations are used for continuous variables;
p-value <0.05 is considered statistically signiﬁcant
A ospi
a
q
b
o
r
a
o
ﬁ
(
u
e
p
o
o
D
[
[
ﬁ
r
t
a
w
C
B
b
i
t
o
u
a
b
o
o
s
o
D
L
I
s
s
b
a
a
t
7
p
t
h
c
o
r
t
m
p
t
i
i
D
w
3
d
R
D
p
a
D
D
r
t
a
w
C
B
b
i
t
o
u
a
b
o
o
s
o
C
C
o
s
t
t
c
c
mntibiotic  consumption  in  non-teaching  Lebanese  h
ntibiotic  use  was  112  DDD/100BD,  with  an  inter-
uartile range  of  84—428  DDD/100BD.  This  may
e due  to  the  hospitals  type  included  in  the  study
r to  a  more  rigid  implementation  of  antibiotic
estriction programs  as  stressed  by  the  hospital
ccreditation process  undertaken  by  the  Ministry
f Health  in  Lebanon  in  2011.  Nevertheless,  our
nding  is  comparable  to  the  USA  2002—2003  study
79 DDD/100BD)  [22],  while  in  Europe  antibiotic
se was  lower  as  reported  in  France  by  Dumartin
t al.,  37—39  DDD/100BD  [23]  and  43.5  RDD/100
atient days  (median)  with  an  interquartile  range
f 36—48  RDD/100  —  corresponding  to  a  median
f 64.4  DDD/100  (interquartile  range,  53—73
DD/100) in  a  published  study  in  Germany  in  2015
29].  In  Sweden  a  range  of  56—59  DDD/100BD  in
24]  and  58—91  DDD/100BD  in  Denmark  [25]  and
nally  50—70  DDD/100BD  in  the  Netherlands  [26].
In addition,  our  data  ﬁndings  showed  that
egional differences  only  affected  the  consump-
ion of  Penicillins  with  antipseudomonal  activity
nd that  the  decrease  in  the  occupancy  rate
as inversely  proportional  to  the  consumption  of
arbapenems,  Glycopeptides  and  aminoglycosides.
road spectrum  antibiotic  use,  speciﬁcally  car-
apenems  and  fourth  generation  cephalosporins
ncreased  signiﬁcantly  with  the  availability  of  a
ransplantation  unit,  a  service  only  available  in  <4%
f participating  hospitals,  while  only  Carbapenems
se was  signiﬁcantly  higher  in  case  of  availability  of
n oncology  unit.
Number  of  beds,  including  the  number  of  ICU
eds did  not  signiﬁcantly  affect  the  consumption
f antibiotics  including  broad  spectrum  antibi-
tics which  means  that  antibiotic  consumption  data
hould preferably  be  collected  at  ward  level  in
rder to  have  more  accurate  results  to  benchmark.
iscussion
imitations
n  Lebanese  non-teaching  hospitals,  our  data
howed that  antibiotic  consumption  did  not  vary
igniﬁcantly  by  region,  occupancy  rate,  and  num-
er of  beds  including  number  of  ICU  bed  or  the
vailability of  an  oncology  or  a  transplantation  unit.
Results from  our  survey  demonstrated  that
verage antibiotic  consumption  in  Lebanese  non-
eaching  hospitals  excluding  pediatric  cases  was
2.55 DDD/100  BD.  This  value  was  lower  com-
ared to  the  ﬁndings  of  the  ARMed  project  [21]
hat  benchmarked  antibiotic  use  prospectively  in
ospitals from  southern  and  eastern  Mediterranean
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ountries  and  showed  that  the  median  total  antibi-
tic use  was  112  DDD/100BD,  with  an  inter-quartile
ange of  84—428  DDD/100BD.  This  may  be  due  to
he hospitals  type  included  in  the  study  or  to  a
ore rigid  implementation  of  antibiotic  restriction
rograms  as  stressed  by  the  hospital  accredita-
ion process  undertaken  by  the  Ministry  of  Health
n Lebanon  in  2011.  Nevertheless,  our  ﬁnding
s comparable  to  the  USA  2002—2003  study  (79
DD/100BD)  [22], while  in  Europe  antibiotic  use
as lower  as  reported  in  France  by  Dumartin  et  al.,
7—39 DDD/100BD  [23]  and  43.5  RDD/100  patient
ays (median)  with  an  interquartile  range  of  36—48
DD/100 — corresponding  to  a median  of  64.4
DD/100 (interquartile  range,  53—73  DDD/100)  in  a
ublished study  in  Germany  in  2015  [29]. In  Sweden
 range  of  56—59  DDD/100BD  in  [24]  and  58—91
DD/100BD in  Denmark  [25]  and  ﬁnally  50—70
DD/100BD in  the  Netherlands  [26].
In addition,  our  data  ﬁndings  showed  that
egional differences  only  affected  the  consump-
ion of  Penicillins  with  antipseudomonal  activity
nd that  the  decrease  in  the  occupancy  rate
as inversely  proportional  to  the  consumption  of
arbapenems,  Glycopeptides  and  aminoglycosides.
road spectrum  antibiotic  use,  speciﬁcally  car-
apenems  and  fourth  generation  cephalosporins
ncreased signiﬁcantly  with  the  availability  of  a
ransplantation  unit,  a service  only  available  in  <4%
f participating  hospitals,  while  only  Carbapenems
se was  signiﬁcantly  higher  in  case  of  availability  of
n oncology  unit.
Number  of  beds,  including  the  number  of  ICU
eds did  not  signiﬁcantly  affect  the  consumption
f antibiotics  including  broad  spectrum  antibi-
tics  which  means  that  antibiotic  consumption  data
hould preferably  be  collected  at  ward  level  in
rder to  have  more  accurate  results  to  benchmark.
urrent and future developments
urrently,  the  Lebanese  Ministry  of  Health  in  collab-
ration with  the  WHO  is mandating  the  hospitals  to
ubmit their  yearly  susceptibility  testing  results  and
o harmonize  antimicrobial  breakpoints  according
o international  guidelines.  It  will  be  important  to
orrelate reported  data  with  patterns  of  antibiotic
onsumption in  order  to  monitor  progress  toward  a
ore prudent  antibiotic  use  [29,32].onclusion
ur  study  provides  baseline  information  on  antibi-
tic consumption  and  emphasis  on  the  need  to
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generalize  the  ﬁndings  to  encompass  all  hospitals
teaching and  non-teaching  through  the  implemen-
tation of  a  national  database  for  the  periodic
surveillance and  benchmark  of  antibiotic  consump-
tion and  its  correlation  with  changes  in  patterns  of
antibiotic susceptibility  testing.  Continuous  moni-
toring of  antibiotic  use  will  eventually  results  in
optimizing  antibiotic  prescription  and  the  imple-
mentation  of  national  strategies  to  ﬁght  antibiotic
resistance and  improve  patient  safety.
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